Under Turkish law, only entities registered in Türkiye are eligible to obtain a marketing authorization (“MA”) for medicinal products for human use. This requirement compels global pharmaceutical companies intending to engage in business in Türkiye to establish local presence either through forming a subsidiary or teaming up with a local partner such as a distributor. In case of a partnership (e.g., established through a distributorship relationship), transfer of MA will be one of the main topics to be discussed if and when such partnership comes to an end. This article provides an overview of the regulatory framework governing the transfer of MAs in Türkiye, with a particular focus on transfers where there may potentially be a disagreement between the transferor and the transferee.
According to the Regulation on the Licensing of Medicinal Products for Human Use (“Regulation”) and the Guidelines on Conditions Requiring Re-authorisation for Licensed Medicinal Products for Human Use, in order to transfer an MA, certain documents must be submitted to the Turkish Medicine and Medical Device Agency (“TMMDA”), and the relevant procedures must be completed. Transfer process has two main aspects: (i) submission of the transfer application to the TMMDA and (ii) cooperation of the transferor.
In the application for the transfer, the transferee must submit to the TMMDA: (i) a court decision stating that the transfer of MA has been fulfilled, (ii) an execution office decision stating that the license has been sold through forced execution proceedings, or (iii) a transfer agreement executed between the transferee and the transferor before a notary public.
Upon submission of the required documentation and payment of the application fees, the review process will commence where the TMMDA shall look into the application to confirm that all regulatory requirements are met, with a particular focus on whether the transferee is well equipped to manage the respective medicinal product in a responsible manner. The TMMDA shall make an assessment on the application within thirty days of the application date, and can request further information or documents, which would re-start the review period. Once the review process is completed, approval will be granted and the MA registry will be updated to reflect the change in the ownership, and the new holder will assume all rights and responsibilities associated with the authorisation.
Share
Related persons
You can contact us for detailed information.


Legal Information
This briefing is for information purposes; it is not legal advice. If you have questions, please call us. All rights reserved.
You May Be Interested In
10 March 2026
The Constitutional Court Upheld the Constitutionality of the Provision Stipulating that Settlement Decisions Cannot Be Challenged before the Courts
The Constitutional Court’s decision dated 11 December 2025 and numbered E. 2025/185, K. 2025/258 (“Constitutional Court Decision”),…
10 March 2026
Loyalty card practices under increased data protection scrutiny in Türkiye
The Turkish Data Protection Authority (DPA) has issued a principle decision dated 11 February 2026, addressing the widespread practice of…
2 March 2026
Use of Health Declarations in Cosmetic Products
A health declaration is any statement or implication that a product or ingredients within its composition confers a benefit on human health…
19 February 2026
Turkish Competition Law Newsletter – 2026 Winter Issue
Welcome to the 2026 Winter edition of the Paksoy Turkish Competition Law Newsletter series.
17 February 2026
The Constitutional Court Confirmed the Competition Authority’s Power to Conduct On-Site Inspections
The Constitutional Court decision dated 6 November 2025 and numbered E. 2023/174, K. 2025/224 (“Constitutional Court Decision”), published…
17 February 2026
Türkiye’s Digital Copyright Bill under parliamentary review: key takeaways for digital platforms and rightsholders
On 10 December 2025, the Digital Copyright Bill (“Bill”) was submitted to the Presidency of the Turkish Parliament.